Company Overview and News

1
An evening walk down Dalal Street | Sensex jumps 297 pts amid stable rupee and oil prices

2018-10-16 moneycontrol
Bulls kept the momentum going on Dalal Street for third consecutive session on Tuesday as the Sensex gained nearly 300 points and all sectoral indices ended in the green despite mixed global cues. Stable rupee and crude oil prices, and healthy start to September quarter earnings season aided the rally.
BHRYY 500325 500469 500228 RELIANCE TCHQY FEDA 532218 532755 532215 535789 505200 SOUTHBANK 532187 AXISBANK 534816 RIGD FEDS HDFCBANK INFRATEL FEDERALBNK EICHERMOT RLNIY ECQRY AXB INDUSINDBK IBN IDKQY FDBAY JSWSTEEL TECHM AXBKY IBULHSGFIN AXBA ICICIBANK HDB 532174 500180

 
The Federal Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-10-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500469 FEDS FDBAY FEDA FEDERALBNK

 
Federal Bank posts marginal growth in quarterly profit

2018-10-16 livemint
Bengaluru: India’s Federal Bank Ltd posted a 0.9% rise in second-quarter net profit on Tuesday, helped by higher interest income.
500469 FEDS FDBAY FEDA FEDERALBNK

 
The Federal Bank Limited - Financial Result Updates

2018-10-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500469 FEDS FDBAY FEDA FEDERALBNK

 
Share market LIVE updates: Sensex, Nifty likely to open in green; Infosys, Hero MotoCorp Q2 results in focus

2018-10-16 financialexpress
Share market live today: Sensex and Nifty — the key indices of the domestic equity markets — are likely to open in the green on Tuesday tracking higher Asian markets. The SGX Nifty futures were trading 19 points, or 0.18%, higher on the Singapore Exchange, indicating a positive start for the NSE Nifty 50 index.
500469 SPXCF FDBAY FEDA 532756 S68 500182 SPXCY FEDS HEROMOTOCO MAHINDCIE HRTQY FEDERALBNK

 
Infosys, Hero Moto, Crisil results today

2018-10-15 thehindubusinessline
Nine companies, including Infosys will declare their quarterly results for the period ended September 2018 on Tuesday. Others are Crisil, Federal Bank, Hero MotoCorp, J&K Bank, Jyotirgamya Enterprises, Mahindra CIE Automotive, Menon Pistons and Shakti Pumps (India). Focus will be on Hero MotoCorp, as it would be the first automobile company to declare results for the Q2 season. Analysts expect Infosys to report y-o-y growth of 15-18 per cent in net profit.
500469 531727 524816 MENNPIS FDBAY 539246 FEDA 532756 MRZUY 532500 500182 531431 JEL NATCOPHARM MARUTI FEDS HEROMOTOCO MAHINDCIE HRTQY FEDERALBNK SHAKTIPUMP

 
The Federal Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-10-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500469 FEDS FDBAY FEDA FEDERALBNK

1
Google India FY18 standalone net up 33%

2018-10-11 financialexpress
Google India posted a 33% increase in its standalone net profit at Rs 407.2 crore for FY18, according to filings with the Registrar of Companies (RoC) and data platform Tofler.
500469 KMBKY IBN FDBAY FEDA ICICIBANK HDB 532174 500180 KOTAKBANK FEDS HDFCBANK 500247 FEDERALBNK

 
Federal Bank gets nod to sell 45% stake in NBFC arm

2018-10-09 freepressjournal.in
New Delhi: Federal Bank on Monday said the Reserve Bank of India has approved proposal to sell up to 45 per cent stake in NBFC arm Fedfina to private equity firm True North. Earlier in May, the bank’s board had approved 26 per cent strategic investment by True North in Fedbank Financial Services (Fedfina).
500469 FEDS FDBAY FEDA FEDERALBNK

 
Federal Bank gets RBI nod to sell 45% stake in NBFC arm to True North

2018-10-08 financialexpress
Federal Bank Monday said the Reserve Bank has approved proposal to sell up to 45 per cent stake in NBFC arm Fedfina to private equity firm True North. Earlier in May, the board of the private sector bank had approved 26 per cent strategic investment by True North in Fedbank Financial Services Ltd (Fedfina).
500469 FEDS FDBAY FEDA FEDERALBNK

 
Federal Bank gets RBI nod to sell 45% stake in NBFC arm to True North

2018-10-08 moneycontrol
Federal Bank on Monday said the Reserve Bank has approved proposal to sell up to 45 per cent stake in NBFC arm Fedfina to private equity firm True North.
500469 FEDS FDBAY FEDA FEDERALBNK

 
The Federal Bank Limited - Updates

2018-10-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500469 FEDS FDBAY FEDA FEDERALBNK

 
The Federal Bank Limited - Trading Window

2018-10-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500469 FEDS FDBAY FEDA FEDERALBNK

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...